Sugi Predict

Sugi Predict / Compounds / SCHEMBL441970

SCHEMBL441970

SCHEMBL441970

O=C(O)CC[C@@H](C(=O)O)N1C(=O)c2ccccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 1.00
▸ POLB P06746 4/20 1.00
▸ KDM4E B2RXH2 2/20 1.00
▸ HPGD P15428 2/20 1.00
▸ MAPK1 P28482 2/20 1.00
▸ HSD17B10 Q99714 2/20 1.00
▸ TP53 P04637 1/20 1.00
▸ GLA P06280 1/20 1.00
▸ CYP3A4 P08684 1/20 1.00
▸ CYP2D6 P10635 1/20 1.00
▸ ALOX12 P18054 1/20 1.00
▸ NFKB1 P19838 1/20 1.00
▸ APEX1 P27695 1/20 1.00
▸ GAA P10253 2/20 0.64
▸ KMT2A Q03164 3/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ HIF1A Q16665 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ ALOX15 P16050 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7285516 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL29763164 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL411173 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL14991107 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL411110 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL31710840 0.90 ALDH1A1 (0.82) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL9741723 0.90 ALDH1A1 (0.82) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL2172873 0.90 ALDH1A1 (0.81) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL6896852 0.88 ALDH1A1 (0.79) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL6896845 0.88 ALDH1A1 (0.79) ALDH1A1POLBKDM4EHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117512596-A Tin-copper-titanium etching solution 湖北兴福电子材料股份有限公司 2024-02-06 — — CN claimed
CN-116769253-B Geogrid modified polypropylene engineering plastic and preparation method and application thereof 山东路德新材料股份有限公司 2023-12-12 — — CN claimed
WO-2023208514-A1 CHIRAL SEPARATION OF N-PHTHALOYL-D/L-GLUTAMIC ACID F. HOFFMANN-LA ROCHE AG (CH) 2023-11-02 — — WO claimed
CN-116769253-A Geogrid modified polypropylene engineering plastic and preparation method and application thereof 山东路德新材料股份有限公司 2023-09-19 — — CN claimed
CN-109467550-B Synthesis method of phthalic diamide-L-glutamic anhydride 苏州亚科科技股份有限公司 2022-02-18 — — CN claimed
US-9695461-B2 Method for adapting a hydrolytic enzyme to a component that stabilizes the hydrolytic enzyme HENKEL AG & CO. KGAA (DE) 2017-07-04 — — US claimed
US-20140186868-A1 METHOD FOR ADAPTING A HYDROLYTIC ENZYME TO A COMPONENT THAT STABILIZES THE HYDROLYTIC ENZYME HENKEL AG & CO., KGAA (DE) 2014-07-03 — — US claimed
US-8642310-B2 Stabilized liquid tenside preparation comprising enzymes HENKEL AG & CO. KGAA (DE) 2014-02-04 — — US claimed
US-20130143298-A1 STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES HENKEL AG & CO. KGAA (DE) 2013-06-06 — — US claimed
US-8193156-B1 Dipeptides incorporating selenoamino acids with enhanced bioavailability—synthesis, pharmaceutical and cosmeceutical applications thereof SAMI LABS LTD 2012-06-05 — — US claimed
US-8003614-B2 Dipeptides incorporating selenoamino acids with enhanced bioavailability—synthesis, pharmaceutical and cosmeceutical applications thereof SAMI LABS LTD (US) 2011-08-23 — — US claimed
EP-1501938-B1 ANALYSIS OF SUBSTRATE UTILIZATION BY ANIMAL OR PLANT CELLS BIOLOG INC (US) 2009-10-21 — — EP claimed
US-20080026017-A1 Novel Dipeptides incorporating selenoamino acids with enhanced bioavailability- Synthesis, pharmaceutical and cosmeceutical applications thereof SAMI LABS LIMITED (IN) 2008-01-31 — — US claimed
US-20070231338-A1 Production and Use of the Methotrexate-Albumin Conjugate as an Immunosuppressive Agent in Gvhd Sinn, Hannsjörg (DE) 2007-10-04 — — US claimed
EP-1501938-A4 COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS BIOLOG INC (US) 2007-01-03 — — EP claimed
EP-1501938-A2 COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS BIOLOG, INC. (US) 2005-02-02 — — EP claimed
WO-2003089652-A2 COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS BIOLOG, INC. (US) 2003-10-30 — — WO claimed
US-20030162164-A1 Comparative phenotype analysis of cells, including testing of biologically active compounds BIOLOG, INC. 2003-08-28 — — US claimed
JP-57050963-A — — None — — JP disclosed
JP-S5750963-A N-PHTHALOYLGLUTAMIC ACID GAMMA-THIOESTER AND ITS PREPARATION KOHJIN CO LTD 1982-03-25 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080026017-A1 Novel Dipeptides incorporating selenoamino acids with enhanced bioavailability- Synthesis, pharmaceutical and cosmeceutical applications thereof SCLY, CYP2R1, SPR ALDH1A1 365/4885POLB 753/4885KDM4E 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.